SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Addres <u>SMITH IAN</u> (Last)	ss of Reporting Person	n*	2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [VRTX]		ionship of Reporting Perso all applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)
C/O VERTEX P INCORPORATI	HARMACEUTIC ED	()	3. Date of Earliest Transaction (Month/Day/Year) 08/02/2017		EVP, CFO & C	00
50 NORTHERN AVENUE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line)	Check Applicable	
(Street) BOSTON	МА	02210		X	Form filed by One Report Form filed by More than C Person	5
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)		
Common Stock	08/02/2017		М		2,155	A	\$91.05	118,043	D			
Common Stock	08/02/2017		S ⁽¹⁾		500	D	\$152.49(2)(3)	117,543	D			
Common Stock	08/02/2017		S ⁽¹⁾		500	D	\$ 153.57 ⁽³⁾⁽⁴⁾	117,043	D			
Common Stock	08/02/2017		S ⁽¹⁾		700	D	\$154.55 ⁽³⁾⁽⁵⁾	116,343	D			
Common Stock	08/02/2017		S ⁽¹⁾		455	D	\$156.09 ⁽³⁾⁽⁶⁾	115,888	D			
Common Stock								5,306	Ι	401(k)		

	Т			uired, Disposed of s, options, converti	,	Owned		
nversion Exercise ce of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially	10. Ownership Form: Direct (D)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Seci Acq (A) o Disp of (E (Inst	5. Number of Derivative Securities Acquired A) or Disposed of (D) Instr. 3, 4 and 5)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$91.05	08/02/2017		М			2,155	(7)	02/01/2026	Common Stock	2,155	\$0.00	21,552	D	

Explanation of Responses:

1. Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.

2. Open market sales reported on this line occurred at a weighted average price of \$152.49 (range \$152.00 to \$152.76).

3. Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

4. Open market sales reported on this line occurred at a weighted average price of \$153.57 (range \$153.08 to \$154.05).

5. Open market sales reported on this line occurred at a weighted average price of \$154.55 (range \$154.20 to \$154.93).

6. Open market sales reported on this line occurred at a weighted average price of \$156.09 (range \$155.49 to \$156.40).

7. The option vests in 16 quarterly installments from 2/2/2016.

Remarks:

/s/ Omar White, Attorney-in-

Fact

08/04/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.